| This is the talk page for discussing improvements to the Cyproterone acetate article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL |
| Archives: 1 |
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Cyproterone acetate.
|
 | This article is rated B-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | ||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||
|
|
please do not use words like "trangender" or "transsexual". Because they offend the gender identity of people. Thanks :) — Preceding unsigned comment added by Lidia9000 (talk • contribs) 10:52, 22 October 2018 (UTC)
Uhh, no. "Transgender" and "transsexual" are not offensive words. — Preceding unsigned comment added by 24.11.72.84 (talk) 19:23, 14 August 2019 (UTC)
CPA vs Spiro
editIn the Transgender Hormone Therapy section it's mentioned that CPA has "an advantage over spironolactone as an antiandrogen in transgender people, as the combination of estrogen and CPA consistently suppresses testosterone levels into the normal female range whereas estrogen with spironolactone does not.". Unless I've got this wrong, this is technically both a true and false statement: CPA does reduce androgen production far more than Spiro, however it is not an advantage because their respective modes of operation are completely different (in the context of transgender hormone therapy): Spiro works to block the androgen receptors throughout the body, whereas CPA stops the production of the androgens to begin with. Therefore naturally you would see differing androgen levels in people taking CPA vs Spiro, but that's not helpful; you need a different metric to compare the feminizing capability of these medications. Aspenpaw (talk) 06:35, 19 November 2024 (UTC)